Phosphodiesterase 4 (PDE4) is an intracellular
enzyme specifically degrading cAMP, a second messenger exerting inhibitory effects on many inflammatory cells. To investigate whether
GPD-1116 (a
PDE4 inhibitor) prevents murine lungs from developing cigarette
smoke-induced
emphysema, the senescence-accelerated mouse (SAM) P1 strain was exposed to either fresh air or cigarette
smoke for 8 wk with or without
oral administration of
GPD-1116. We confirmed the development of
smoke-induced
emphysema in SAMP1 [air vs.
smoke (means +/- SE); the mean linear intercepts (MLI), 52.9 +/- 0.8 vs. 68.4 +/- 4.2 microm, P < 0.05, and destructive index (DI), 4.5% +/- 1.3% vs. 16.0% +/- 0.4%, P < 0.01].
Emphysema was markedly attenuated by
GPD-1116 (MLI = 57.0 +/- 1.4 microm, P < 0.05; DI = 8.2% +/- 0.6%, P < 0.01) compared with
smoke-exposed SAMP1 without
GPD-1116.
Smoke-induced apoptosis of lung cells were also reduced by administration of
GPD-1116.
Matrix metalloproteinase (MMP)-12 activity in bronchoalveolar lavage fluid (BALF) was increased by
smoke exposure (air vs.
smoke, 4.1 +/- 1.1 vs. 40.5 +/- 16.2 area/microg
protein; P < 0.05), but
GPD-1116 significantly decreased MMP-12 activity in
smoke-exposed mice (5.3 +/- 2.1 area/microg
protein). However,
VEGF content in lung tissues and BALF decreased after
smoke exposure, and the decrease was not markedly restored by
oral administration of
GPD-1116. Our study suggests that
GPD-1116 attenuates
smoke-induced
emphysema by inhibiting the increase of
smoke-induced MMP-12 activity and protecting lung cells from apoptosis, but is not likely to alleviate cigarette
smoke-induced decrease of
VEGF in SAMP1 lungs.